Metformin to slow lung decline in idiopathic pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether metformin, a common diabetes medication, can slow the worsening of lung function in people with idiopathic pulmonary fibrosis (IPF)—a serious condition where lung tissue becomes scarred and stiff. Researchers believe metformin may help protect lungs from further damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IPF (idiopathic pulmonary fibrosis) by a lung specialist
- You are 40 years old or older
- Your blood sugar control is reasonably good (HbA1c below 9%)
- You have not taken metformin in the past 3 months
- If you take other IPF medications, you must have been on a stable dose for at least 8 weeks
- You are able to swallow pills and provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This study tests if the diabetes drug metformin can slow down aging-related lung decline in people with COPD. You may qualify if you have moderate-to-severe COPD with emphysema and a history of smoking.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.